Conclusion
oligometastatic CRPC
METASTASES
This protocol describes the design of a randomized, open-label, phase II, multicenter trial that will evaluate the efficacy of radium-223 in combination with metastatic site-directed radiation therapy in patients with oligometastatic CRPC whose metastases are confined to bone. It is hoped that the results of this study will provide a sound basis for a prospective, randomized phase III trial.